MCM
NVO

Marathon Capital Management’s Novo Nordisk NVO Stock Holding History

Marathon Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75M Sell
78,134
-3,430
-4% -$147K 0.76% 41
2026
Q1 		$3M Sell
81,564
-1,141
-1% -$54.1K 0.67% 43
2025
Q4 		$4.21M Buy
82,705
+25,230
+44% +$1.29M 0.91% 39
2025
Q3 		$3.19M Buy
+57,475
New +$3.36M 0.73% 41

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Marathon Capital Management's NVO Position: Q2 2026 in Review

Marathon Capital Management reduced its Novo Nordisk (NVO) stake by 4.2% in Q2 2026, selling an estimated $147K and leaving 78,134 shares worth $3.75M. The position accounts for 0.76% of the portfolio, ranked #41.

Marathon Capital Management first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.21M in Q4 2025. 1,352 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Marathon Capital Management held 78,134 shares of Novo Nordisk worth $3.75M as of Q2 2026.
  • Marathon Capital Management sold 3,430 Novo Nordisk shares in Q2 2026, an estimated $147K.
  • Novo Nordisk made up 0.76% of Marathon Capital Management's portfolio in Q2 2026, its #41 holding.
  • Marathon Capital Management first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
  • Marathon Capital Management's Novo Nordisk position peaked at $4.21M in Q4 2025.
  • 1,352 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.